🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Randomized Masked Trial of Injectable Cross-Linked Hyaluronic Acid for Moderate-to-Severe Nasolabial Folds
NCT07367204Nasolabial Fold Wrinkles
Chongqing Jinsaixing Medical Technology Co., Ltd
Not applicable
356
Beijing
2025-02-24
Recruiting
Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.
NCT06928922Advanced Lung Cancer, Lung Metastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
83
Beijing
2025-02-24
Recruiting
Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia
NCT07080931Androgenetic Alopecia
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Phase 3
294
Beijing
2025-02-24
Recruiting
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
NCT06741644Advanced Solid Tumors
DrugsLeucovorin·Etoposide·Irinotecan·Ivonescimab
CStone Pharmaceuticals
Phase 1/2
800
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-02-24
Recruiting
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
NCT06832982Advanced Solid Tumors
Shanghai Pushi Medical Science Co. Ltd
Phase 1
66
Beijing, Fujian, Zhejiang, Heilongjiang, Shandong, Guangdong, Shenyang, Hebei
2025-02-24
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
NCT06809764Non-small Cell Lung Cancer
Daiichi Sankyo
Observational
150
Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei
2025-02-21
Recruiting
Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).
NCT06601127Ischemic Stroke
DrugClopidogrel
Tianjin Institute of Pharmaceutical Research Co., Ltd
Phase 2
600
Shenyang, Beijing
2025-02-21
Recruiting
CD123-CD16-NK Cells Immunotherapy for AML
NCT06835140AML (Acute Myelogenous Leukemia), NK Cell, CD123+ Acute Myeloid Leukemia
Chunji Gao
Phase 1
9
Beijing
2025-02-21
Recruiting
The Cohort Construction Project of Peking University Third Hospital
NCT07761676Multiple Chronic Conditions (Unspecified), Large-scale Health Examination Cohort
Peking University Third Hospital
Observational
100,000
Beijing
2025-02-21
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
552
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Linyi
2025-02-21
Recruiting
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
NCT06822881Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Beijing GoBroad Hospital
Phase 1
27
Beijing
2025-02-20
Recruiting
Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis
NCT06983951Light Chain Amyloidosis
Beijing Boren Hospital
Not applicable
30
Beijing
2025-02-20
Recruiting
Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
NCT06993493Autoimmune Disease
Beijing Boren Hospital
Not applicable
12
Beijing
2025-02-20
Not yet open
Comparison of Physiological Effects of Two Types of High-Flow Oxygen Therapy in Tracheostomized Patients
NCT06816745Critical Care, Oxygen Therapy, Tracheostomy
Jian-Xin Zhou
Not applicable
20
Beijing
2025-02-20
Recruiting
Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
NCT06983964Autoimmune Disease
Beijing Boren Hospital
Not applicable
12
Beijing
2025-02-20
Recruiting
Safety and Efficacy Evaluation of Sodium Hyaluronate 32mg/ml in Improving Facial Skin Dryness and Dullness
NCT06914583Facial Dryness, Facial Dullness
IBSA Farmaceutici Italia Srl
Not applicable
500
Beijing, Changde, Chengdu, Shanghai, Xi'an
2025-02-19
Recruiting
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
NCT07157969HCC - Hepatocellular Carcinoma
DrugsApatinib·Camrelizumab·Atezolizumab·Lenvatinib
Peking Union Medical College Hospital
Phase 2
300
Beijing
2025-02-19
Not yet open
Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
NCT06839339Wet Age-related Macular Degeneration (wAMD)
Beijing Anlong Biopharmaceutical Co., Ltd.
Phase 2
40
Beijing
2025-02-18
Active, closed
KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
NCT06767046Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)
Corregene Biotechnology Co., Ltd
Phase 1
8
Beijing
2025-02-18
Recruiting
Echocardiography Guided TAVR (Echo TAVR)
NCT07030062Transcatheter Aortic Valve Replacemen, Echocardiography
Pan Xiangbin
Observational
20
Beijing
2025-02-18
Not yet open
ExCR's Effects and Safety in Vulnerable ADHF Patients
NCT06795737Acute Decompensated Heart Failure (ADHF)
YE Jing
Not applicable
88
Beijing
2025-02-17
Recruiting
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
NCT06481735Acute Lymphocytic Leukemia
DrugsFludarabine·Cyclophosphamide
Chinese PLA General Hospital
Phase 1/2
30
Beijing, Changzhi, Tianjin
2025-02-15
Not yet open
Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002
NCT06834438NF2 Deficiency
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
9
Beijing
2025-02-15
Not yet open
QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC
NCT06750861Pancreatic Adenocarcinoma
DrugIparomlimab and Tuvonralimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2025-02-15
Not yet open
Pulsed Field Ablation Versus Radiofrequency Ablation for Persistent Atrial Fibrillation
NCT06791629Persistent Atrial Fibrillation, Radiofrequency Catheter Ablation, Pulsed Field Ablation
Beijing Anzhen Hospital
Not applicable
700
Beijing
2025-02-15
Recruiting
Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
NCT06874946Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma, PTCL
Peking University People's Hospital
Phase 1/2
30
Beijing
2025-02-14
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819Advanced Solid Tumors, HER2 Mutation
Bayer
Phase 2
111
Beijing, Changsha, Shanghai, Hangzhou
2025-02-13
Recruiting
Efficacy of Thermal Ablation Combined With Antithyroid Drugs in the Treatment of Primary Hyperthyroidism
NCT07557810Complication Rate, Efficacy and Safety, Hyperthyroidism/Thyrotoxicosis, Cure Rate
Chinese PLA General Hospital
Observational
454
Beijing
2025-02-13
By invitation
Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis
NCT07103863AL Amyloidosis (AL), Cardiac Amyloidosis
Beijing Anzhen Hospital
Observational
49
Beijing
2025-02-13
Recruiting
A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
NCT06717750Advanced Malignant Solid Tumors
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Phase 1
102
Beijing, Shenyang
2025-02-13
By invitation
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226Developmental and Epileptic Encephalopathy
DrugLP352
Longboard Pharmaceuticals
Phase 3
324
Beijing, Guangzhou, Wuhan, Shanghai Shi
2025-02-12
Recruiting
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
NCT06738251Advanced Urothelial Carcinoma
DrugsPemetrexed Disodium·SHR-A2102·Gemcitabine Hydrochloride·Docetaxel
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 3
402
Beijing
2025-02-12
By invitation
Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma
NCT07126990Glioma
Xiaorong Wu
Phase 1/2
40
Beijing
2025-02-12
Recruiting
"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"
NCT06829355MCRC
DrugsThymalfasin·Regorafenib·Tislelizumab
Beijing Friendship Hospital
Phase 2
52
Beijing
2025-02-11
Recruiting
A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT06822868B-Cell Non-Hodgkin Lymphoma
Kai Hu
Phase 1
24
Beijing
2025-02-10
Recruiting
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
NCT06642545Breast Cancer
DrugsRC148·Disitamab Vedotin·Toripalimab
RemeGen Co., Ltd.
Phase 2
40
Beijing
2025-02-10
Recruiting
Study on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension
NCT06980584Fibrosing Mediastinitis, Pulmonary Hypertension
Beijing Chao Yang Hospital
Not applicable
48
Beijing
2025-02-10
Active, closed
Testing the Effectiveness of AI Chatbots to Improve Public Knowledge and Attitudes Towards Depression
NCT06858371Depression Literacy, Depression Disorders, Stigma of Mental Illness
Peking University
Not applicable
200
Beijing
2025-02-10
Recruiting
Epidural Spinal Cord Stimulation for Lower-limb Impairment in Adrenomyeloneuropathy
NCT06796920Adrenomyeloneuropathy Without Cerebral Involvement
Third Military Medical University
Not applicable
10
Beijing, Chongqing, Jingmen
2025-02-10
Recruiting
Goal-directed Hemodynamic Management and Kidney Injury After Radical Nephrectomy or Nephroureterectomy
NCT05149196Nephrectomy, Nephroureterectomy, Hemodynamic Management, Acute Kidney Injury
Peking University First Hospital
Not applicable
1,724
Beijing
2025-02-10
Recruiting
Chinese Rheumatism Biobank(CRB)
NCT06887517Lupus Erythematosus, Systemic
Chinese SLE Treatment And Research Group
Observational
300
Beijing
2025-02-10
Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy
DrugClaseprubart
Dianthus Therapeutics
Phase 3
256
Hefei, Guangzhou, Changsha, Wuhan, Chifeng, Suzhou, Beijing, Chengdu
2025-02-10
Active, closed
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293Menstrual Migraine (MM)
DrugAtogepant
AbbVie
Phase 3
468
Beijing, Guangzhou, Shijiazhuang, Wuhan, Suzhou, Xi'an, Taiyuan, Tianjin
2025-02-10
Not yet open
Clinical Classification of MAFLD Based Liver Biopsy
NCT06795646Metabolic Dysfunction Associated Steatotic Liver Disease, Metabolic Dysfunction-associated Steatohepatitis (MASH)
Beijing Friendship Hospital
Observational
2,000
Beijing, Hangzhou, Shanghai, Tianjin
2025-02-08
Recruiting
Perioperative Cerebral Function Assessment for Cardiac Surgery
NCT06660602Cardiac Surgery
China National Center for Cardiovascular Diseases
Observational
1,845
Beijing
2025-02-08
Recruiting
Defocus-Enhanced vs. Single Vision Spectacles in Myopia Control Visual Function Training
NCT06821074Myopia
Beijing Visionly Plus Eye Hospital
Not applicable
1,000
Beijing
2025-02-08
Recruiting
Efficacy of Esketamine for Patients With Irritable Bowel Syndrome
NCT06788444Irritable Bowel Syndrome
DrugEsketamine
Beijing Tiantan Hospital
Not applicable
552
Beijing
2025-02-08
Recruiting
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
NCT06767527Triple-Negative Breast Cancer (TNBC)
DrugsIvonescimab·Nab-paclitaxel
Akeso
Phase 3
416
Beijing
2025-02-07
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
DrugsRemibrutinib treatment·Remibrutinib
Novartis Pharmaceuticals
Phase 3
180
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing
2025-02-07
Recruiting
The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction
NCT06732648Severe Cerebral Edema Following Large Hemispheric Infarction
Beijing Suncadia Pharmaceuticals Co., Ltd
Phase 2/3
725
Beijing
2025-02-07
Recruiting
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
NCT06773091Advanced Solid Tumors
Shanghai NK Cell Technology Co., LTD
Phase 1
76
Beijing
2025-02-07
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834360Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
216
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Jinan, Jingzhou, Nanning
2025-02-06
Recruiting
Effect of RNS in Treatment-refractory Tourette's Syndrome
NCT06785532Tourette Syndrome
Xuanwu Hospital, Beijing
Not applicable
10
Beijing
2025-02-05
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Shanghai, Shenzhen
2025-02-05
Not yet open
The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
NCT06773221Metabolic Dysfunction Associated Fatty Liver Disease, Compensated Liver Cirrhosis
DrugChiglitazar
Beijing Friendship Hospital
Not applicable
195
Beijing
2025-02-05
Recruiting
RNS for Treatment-resistant Obsessive-compulsive Disorder
NCT06782867Obsessive-Compulsive Disorder (OCD)
Xuanwu Hospital, Beijing
Not applicable
10
Beijing
2025-02-05
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin
BioNTech SE
Phase 3
621
Changchun, Baoding, Beijing, Bengbu, Fuzhou, Guangzhou, Hangzhou, Ha’erbin
2025-02-03
Recruiting
Optimizing Prostate Biopsy Schemes in Men With Multiple MRI Visible Lesions
NCT06841211Prostate Cancer
Peking University First Hospital
Not applicable
572
Beijing
2025-02-01
Not yet open
QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer
NCT06751277Recurrent or Metastatic Endometrial Cancer
DrugsIparomlimab and Tuvonralimab·Carboplatin
xiang yang
Phase 2
26
Beijing
2025-02-01
Recruiting
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881Hereditary Angioedema (HAE)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
170
Beijing
2025-02-01
Recruiting
Efficacy and Central Mechanisms of Electroacupuncture for Medication Overuse Headache
NCT06802471Medication Overuse Headache, Electroacupuncture
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
160
Beijing
2025-02-01
Not yet open
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer
NCT06745193Advanced Esophageal Carcinoma
Peking University
Phase 2
63
Beijing
2025-02-01
Not yet open
A Multicentric Cohort of Autoimmune Encephalitis
NCT06760091Autoimmune Encephalitis
Xuanwu Hospital, Beijing
Observational
200
Beijing
2025-02-01
Recruiting
A Chinese Multicenter Study on Surgical Techniques and Outcomes Across the Lifespan in Congenital Heart Disease
NCT07524998Congenital Heart Disease, Complex Congenital Heart Disease, Surgery (Cardiac), Perioperative Care
China National Center for Cardiovascular Diseases
Observational
3,000
Beijing
2025-02-01
Not yet open
A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps
NCT06801353Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Biological Therapy, Biomarkers
DrugsMometasone furoate·Stapokibart
Beijing Tongren Hospital
Phase 4
90
Beijing
2025-02-01
Not yet open
A Multicenter Study of Artificial Intelligence Model for Fetal Congenital Heart Disease
NCT06796127Congenital Heart Disease (CHD), Artificial Intelligence (AI)
Beijing Anzhen Hospital
Observational
10,000
Beijing
2025-02-01
Not yet open
Adjuvant Cerebroprotection Using Normobaric Hyperoxia in Pre-hospital Patients with Suspected Stroke
NCT06801457Stroke Acute
Capital Medical University
Phase 3
1,000
Beijing
2025-02-01
Recruiting
Chronic Airway Disease and Multimorbidity Cohort
NCT06798077Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
China-Japan Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Shenyang, Xi'an, Shanghai
2025-02-01
Recruiting
Feasibility, Safety, and Preliminary Efficacy of Median Nerve Stimulation for Cognitive Dysfunction in Patients With Acute Traumatic Brain Injury
NCT07413562Traumatic Brain Injury, Cognitive Dysfunction
Beijing Tiantan Hospital
Not applicable
30
Beijing
2025-02-01
Recruiting
The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System
NCT07136025Asthma
Beijing Chao Yang Hospital
Not applicable
200
Beijing, Guangzhou, Zhengzhou, Changsha, Shenyang, Shanghai, Taiyuan, Hangzhou
2025-02-01
Not yet open
Efficacy and Safety of Chinese Herbal HuoXue LiShui Formula for Chronic Subdural Hematoma
NCT06427980Chronic Subdural Hematoma
Beijing Tiantan Hospital
Not applicable
160
Beijing, Lianyungang
2025-02-01
Not yet open
Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer
NCT06784206Small Cell Lung Cancer, Limited Stage, Hyperfractionated Accelerated Radiotherapy, Simultaneous Radiotherapy and Chemotherapy
Peking University Cancer Hospital & Institute
Phase 2
30
Beijing
2025-02
Recruiting
Safety and Efficacy of Using a Novel Full Visual Access Platform System in Transvaginal Hysterectomy
NCT06658145Uterine Myoma, Surgery, Laparoscopic
China-Japan Friendship Hospital
Not applicable
94
Beijing
2025-02
Not yet open
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
NCT06791772Systemic Lupus Erythematosus
DrugCM313
Keymed Biosciences Co.Ltd
Phase 2
150
Beijing
2025-02
Recruiting
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
NCT06841042System Lupus Erythematosus
Sinocelltech Ltd.
Phase 1/2
168
Beijing, Changchun, Guangzhou, Hangzhou, Jiujiang, Kunming, Linfen, Mianyang
2025-02
Not yet open
Effect of Oral Supplements for Influenza Vaccine Response
NCT06827873Influenza Vaccine Response
DrugTUDCA (Tauroursodeoxycholic Acid) Supplementation
Tsinghua University
Not applicable
45
Beijing
2025-02
Not yet open
SMART Study in Real World
NCT06780696Hypertension, Uncontrolled Hypertension, Resistant Hypertension, Reduce Antihypertensive Drug Burden
SyMap Medical (Suzhou), Ltd.
Observational
1,000
Beijing
2025-02
Not yet open
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
NCT06779097Moderate to Severe Plaque Psoriasis
DrugVunakizumab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 4
1,564
Beijing
2025-02
Not yet open
The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis
NCT06833307Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis
DrugSHR-1314
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
90
Beijing, Shanghai
2025-02
Recruiting
Safety and Preliminary Efficacy of NXL-001 in Patients With Ischemic Stroke
NCT06761183Ischemic Stroke
Beijing Tiantan Hospital
Phase EARLY_PHASE1
9
Beijing
2025-01-31
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Beijing, Guangzhou, Jinan, Tianjin, Zhengzhou
2025-01-30
Not yet open
Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma
NCT06798194Hepatocellular Carcinoma
Chinese PLA General Hospital
Observational
300
Beijing
2025-01-30
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hefei, Beijing, Guangzhou, Wuhan, Harbin, Changsha, Chengdu, Hangzhou
2025-01-29
By invitation
Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease
NCT06809413Fluoroquinolone, Mycobacterium
DrugSitafloxacin
Beijing Chest Hospital
Phase 2
12
Beijing
2025-01-28
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Prednisolone·Methylprednisolone
Merck Sharp & Dohme LLC
Phase 3
1,046
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Guiyang
2025-01-27
Recruiting
Usability User Testing of the Easy-EyeFM AI Platform
NCT06834906Ocular Diseases
Tsinghua University
Not applicable
84
Beijing
2025-01-26
Recruiting
Minimum Effective Dose of Incisional Local Infiltration Betamethasone for the Prevention of Pain After Spinal Surgery
NCT06785350Pain Management, Spine Surgery
Beijing Tiantan Hospital
Not applicable
535
Beijing
2025-01-25
Recruiting
Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
NCT06789679Pancreatic Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
128
Beijing
2025-01-25
Recruiting
Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A
NCT06802055Aplastic Anaemia
DrugsCyclosporin A·Sirolimus
Peking Union Medical College Hospital
Phase 2
40
Beijing
2025-01-25
Recruiting
Diagnosis and Allergen Identification of Perioperative Anaphylaxis
NCT06793163Perioperative/Postoperative Complications, Anaphylaxis, Tryptase, Allergens
Peking University First Hospital
Observational
115
Beijing
2025-01-25
Recruiting
Assessing the Efficacy of a Preoperative Navigation System in Anterior Cruciate Ligament Reconstruction
NCT06858930Anterior Cruciate Ligament Rupture
Beijing Tsinghua Chang Gung Hospital
Not applicable
76
Beijing
2025-01-24
Recruiting
SPG Pulsed Radiofrequency for Chronic Cluster Headache
NCT06787677Headache, Cluster
Beijing Tiantan Hospital
Not applicable
108
Beijing
2025-01-24
Recruiting
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
NCT06761417Solid Tumors, Children, Adolescents
DrugsMitoxantrone liposome·Anlotinib·Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
49
Beijing
2025-01-24
Active, closed
A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)
NCT06812117Diabetic Peripheral Neuropathic Pain
Daiichi Sankyo
Observational
721
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2025-01-24
Not yet open
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
NCT06767540Atopic Dermatitis
Akeso
Phase 3
198
Wuhu, Beijing, Chongqing, Dongguan, Guangzhou, Jiangmen, Shenzhen, Zhuhai
2025-01-23
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005Advanced Metastatic Castration Resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
84
Beijing, Fuzhou, Foshan, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang
2025-01-23
Recruiting
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
NCT06793189Marginal Zone Lymphoma(MZL)
DrugOrelabrutinib
Ruijin Hospital
Phase 2
145
Shanghai, Shenyang, Beijing
2025-01-23
Recruiting
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
NCT06698796Dermatomyositis, Polymyositis
Pfizer
Phase 3
211
Hefei, Nanchang, Shanghai, Kunming, Beijing
2025-01-22
Recruiting
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414Higher-risk Myelodysplastic Syndrome
DrugsLisaftoclax·Azacitidine
Ascentage Pharma Group Inc.
Phase 3
490
Beijing
2025-01-22
Active, closed
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
NCT06478212IDH1-mutant Glioma, IDH2-mutant Glioma
DrugsVorasidenib·Temozolomide
Institut de Recherches Internationales Servier
Phase 1/2
51
Beijing, Shanghai
2025-01-22
Rows per page Showing 2601–2700 of 5484
Previous 25 26 27 28 29 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=27

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.